November #29 : Twisted Sisters

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Elizabeth Taylor Tells the Truth

S.O.S.

Letters to the Editor-November 1997

The Last Auction Hero

Suicide Ride

Twisted Sisters

Kiss Hysteria

French Toast

Code Blue

Coffee Talk

A Spot of Pot

Shalala Infections

Child’s Play

Hurray for Hollywood!

Say What - November 1997

Obituaries - November 1997

Tribute - Nigel Finch

True Brit

Baste Not, Want Not

Suicide Watch

Passage From India



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

November 1997

Twisted Sisters

Gene mutations linked to disease delay

Do your eyes glaze over when reading about CCR5 and its kin, CCR2? Get over it. These "gateways for the virus" have helped trigger a research explosion in gene-based therapy. CCR5 first hit it big last year with the discovery that double and single genetic mutations in this CD4-cell receptor block HIV infection and delay progression to full-blown AIDS, respectively. Then, in an August "Eureka1', a National Cancer Institute (NCI) team led by Stephen O'Brien reported that blood tests of 3,000 long-term survivors showed that 30 percent ha a mutation in yet another receptor, CCR2, which apparently works independently of CCR5. According to the study in September's Science, people with this molecular morph develop AIDS three to four years later than those with the unaltered gene. The bottom-line for PWAs? "These altered genes tells us that nature has already devised an anti-HIV therapy without significant side effects," O'Brien said. "If we can mimic the effects of these mutations, it may be possible to develop treatments that delay the onset of AIDS." In fact, two such drugs are nearing clinical trials.

But then Danish scientists detected a burst of static in all this co-receptor reception: In a study of 99 men with HIV, the one-fifth with the single CCR5 mutation, once diagnosed, died much faster. Shaken, O'Brien's team analyzed the blood of 2,000 people from five AIDS cohorts and found that the CCR5 variation did not quicken their diagnosis-to-death frequency. A second NIH study confirmed these results. In a letter in October's Lancet, O'Brien debunks the Danish data, burnishing the buzz on the genes.



[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.